- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Virtual Event – Current Guidelines & Unmet Needs In The Treatment Of Agitation Associated With Alzheimer’s Dementia

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Current Guidelines & Unmet Needs In The Treatment Of Agitation Associated With Alzheimer’s Dementia
This is a Virtual Event for PsychU members in Alaska, Idaho, Montana, Oregon, Utah, and Washington.
Individualized and multimodal treatment plans are recommended for patients with Alzheimer’s disease and Agitation associated with Alzheimer’s Dementia (AAD). There is a need for better identification of AAD. There is also a need for approved pharmacological treatments that have proven and favorable benefit: risk profiles to reduce symptoms and ultimately improve burden to caregivers and healthcare.
In this discussion, current treatment guidelines, assess risk/benefit profile, and discuss unmet needs of AAD treatment will be reviewed.

Michael Aldape, PhD
Senior Medical Science Liaison

Simon Kim, PharmD
Medical Science Liaison
Speakers Michael Aldape, PhD and Simon Kim, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)